Cue Biopharma, Inc.
US ˙ NasdaqCM ˙ US22978P1066

Introduction

This page provides a comprehensive analysis of the known insider trading history of Simon Barry J.. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Simon Barry J. has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:IBRX / ImmunityBio, Inc. Director 3,243,571
US:VIRX / Viracta Therapeutics, Inc. Director 80,000
US:CUE / Cue Biopharma, Inc. Director 10,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Simon Barry J.. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases CUE / Cue Biopharma, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CUE / Cue Biopharma, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CUE / Cue Biopharma, Inc. Insider Trades
Insider Sales CUE / Cue Biopharma, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CUE / Cue Biopharma, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

CUE / Cue Biopharma, Inc. Insider Trades
Insider Purchases IBRX / ImmunityBio, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in CUE / Cue Biopharma, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IBRX / ImmunityBio, Inc. Insider Trades
Insider Sales IBRX / ImmunityBio, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in CUE / Cue Biopharma, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2021-05-25 IBRX Simon Barry J. 88,787 16.1828 88,787 16.1828 1,436,822 351 2.6800 -1,198,873 -83.44
2021-05-24 IBRX Simon Barry J. 21,223 16.0237 21,223 16.0237 340,071
2021-05-21 IBRX Simon Barry J. 14,990 16.0883 14,990 16.0883 241,164
2016-09-08 NK Simon Barry J. 30,000 7.4000 30,000 7.4000 222,000
2016-09-07 NK Simon Barry J. 2,000 8.8356 2,000 8.8356 17,671

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IBRX / ImmunityBio, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Simon Barry J. as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-02-25 2025-02-22 4 IBRX ImmunityBio, Inc.
Common Stock
F - Taxes -5,453 3,243,571 -0.17 3.42 -18,649 11,093,013
2025-02-25 2025-02-22 4 IBRX ImmunityBio, Inc.
Common Stock
M - Exercise 15,243 3,249,024 0.47
2025-01-24 2025-01-22 4 IBRX ImmunityBio, Inc.
Common Stock
M - Exercise 110,020 3,233,781 3.52 2.00 219,864 6,462,388
2024-02-02 2024-01-31 4 IBRX ImmunityBio, Inc.
Common Stock
F - Taxes -22,094 3,123,761 -0.70 3.36 -74,236 10,495,837
2024-02-02 2024-01-31 4 IBRX ImmunityBio, Inc.
Common Stock
M - Exercise 57,200 3,145,855 1.85
2023-09-06 2023-09-01 4 IBRX ImmunityBio, Inc.
Common Stock
M - Exercise 57,199 3,088,655 1.89
2022-03-25 2022-03-23 4 IBRX ImmunityBio, Inc.
Stock Option (right to buy)
A - Award 10,714 10,714
2022-01-28 2021-06-04 5 IBRX ImmunityBio, Inc.
Common Stock
G - Gift -71,051 3,031,456 -2.29
2021-05-25 2021-05-25 4 IBRX ImmunityBio, Inc.
Common Stock
S - Sale -88,787 3,102,507 -2.78 16.18 -1,436,822 50,207,250
2021-05-25 2021-05-24 4 IBRX ImmunityBio, Inc.
Common Stock
S - Sale -21,223 3,191,294 -0.66 16.02 -340,071 51,136,338
2021-05-25 2021-05-21 4 IBRX ImmunityBio, Inc.
Common Stock
S - Sale -14,990 3,212,517 -0.46 16.09 -241,164 51,683,937
2021-05-07 2021-05-05 4 IBRX ImmunityBio, Inc.
Stock Option (right to buy)
M - Exercise -56,967 0 -100.00
2021-05-07 2021-05-05 4 IBRX ImmunityBio, Inc.
Common Stock
M - Exercise 56,967 3,227,507 1.80 1.75 99,943 5,662,338
2021-03-30 2021-03-26 4 VIRX Viracta Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 80,000 80,000
2021-02-08 2021-02-05 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -22,100 110,020 -16.73
2021-02-08 2021-02-05 4 NK NantKwest, Inc.
Common Stock
S - Sale X -22,100 3,170,540 -0.69 23.09 -510,267 73,204,598
2021-02-08 2021-02-05 4 NK NantKwest, Inc.
Common Stock
M - Exercise 22,100 3,192,640 0.70 2.00 44,165 6,380,172
2021-02-04 2021-02-02 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -82,070 132,120 -38.32
2021-02-04 2021-02-02 4 NK NantKwest, Inc.
Common Stock
S - Sale X -82,070 3,170,540 -2.52 20.65 -1,694,803 65,473,870
2021-02-04 2021-02-02 4 NK NantKwest, Inc.
Common Stock
M - Exercise 82,070 3,252,610 2.59 2.00 164,009 6,500,016
2021-01-29 2021-01-28 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -11,304 214,190 -5.01
2021-01-29 2021-01-28 4 NK NantKwest, Inc.
Common Stock
S - Sale X -11,304 3,170,540 -0.36 20.53 -232,121 65,105,137
2021-01-29 2021-01-28 4 NK NantKwest, Inc.
Common Stock
M - Exercise 11,304 3,181,844 0.36 2.00 22,590 6,358,597
2021-01-29 2021-01-27 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -36,626 225,494 -13.97
2021-01-29 2021-01-27 4 NK NantKwest, Inc.
Common Stock
S - Sale X -36,626 3,170,540 -1.14 20.61 -754,946 65,352,122
2021-01-29 2021-01-27 4 NK NantKwest, Inc.
Common Stock
M - Exercise 36,626 3,207,166 1.16 2.00 73,193 6,409,201
2021-01-06 2021-01-04 4 CUE Cue Biopharma, Inc.
Stock Option (right to buy)
A - Award 10,000 10,000
2020-12-28 2020-12-22 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -130,000 262,120 -33.15
2020-12-28 2020-12-22 4 NK NantKwest, Inc.
Common Stock
S - Sale X -130,000 3,170,540 -3.94 18.05 -2,346,604 57,230,783
2020-12-28 2020-12-22 4 NK NantKwest, Inc.
Common Stock
M - Exercise 130,000 3,300,540 4.10 2.00 259,792 6,595,799
2020-07-22 2020-07-21 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -1,565 392,120 -0.40
2020-07-22 2020-07-21 4 NK NantKwest, Inc.
Common Stock
S - Sale X -1,565 3,170,540 -0.05 15.50 -24,258 49,144,638
2020-07-22 2020-07-21 4 NK NantKwest, Inc.
Common Stock
M - Exercise 1,565 3,172,105 0.05 2.00 3,127 6,339,135
2020-07-22 2020-07-20 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -87,705 393,685 -18.22
2020-07-22 2020-07-20 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -40,730 56,967 -41.69
2020-07-22 2020-07-20 4 NK NantKwest, Inc.
Common Stock
S - Sale X -128,435 3,170,540 -3.89 15.53 -1,995,071 49,250,217
2020-07-22 2020-07-20 4 NK NantKwest, Inc.
Common Stock
M - Exercise 87,705 3,298,975 2.73 2.00 175,270 6,592,672
2020-07-22 2020-07-20 4 NK NantKwest, Inc.
Common Stock
M - Exercise 40,730 3,211,270 1.28 1.76 71,497 5,637,063
2020-07-10 2020-07-08 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -39,950 97,697 -29.02
2020-07-10 2020-07-08 4 NK NantKwest, Inc.
Common Stock
S - Sale X -39,950 3,170,540 -1.24 13.14 -524,759 41,646,311
2020-07-10 2020-07-08 4 NK NantKwest, Inc.
Common Stock
M - Exercise 39,950 3,210,490 1.26 1.76 70,128 5,635,694
2020-07-02 2020-06-30 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -9 137,647 -0.01
2020-07-02 2020-06-30 4 NK NantKwest, Inc.
Common Stock
S - Sale X -9 3,170,540 0.00 13.00 -117 41,217,020
2020-07-02 2020-06-30 4 NK NantKwest, Inc.
Common Stock
M - Exercise 9 3,170,549 0.00 1.76 16 5,565,582
2020-06-23 2020-06-23 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -29,609 137,656 -17.70
2020-06-23 2020-06-23 4 NK NantKwest, Inc.
Common Stock
S - Sale X -29,609 3,170,540 -0.93 13.01 -385,133 41,240,165
2020-06-23 2020-06-23 4 NK NantKwest, Inc.
Common Stock
M - Exercise 29,609 3,200,149 0.93 1.76 51,976 5,617,542
2020-06-23 2020-06-22 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -136,729 167,265 -44.98
2020-06-23 2020-06-22 4 NK NantKwest, Inc.
Common Stock
S - Sale X -10,432 3,170,540 -0.33 13.01 -135,709 41,245,238
2020-06-23 2020-06-22 4 NK NantKwest, Inc.
Common Stock
S - Sale X -80,000 3,180,972 -2.45 10.55 -843,664 33,545,895
2020-06-23 2020-06-22 4 NK NantKwest, Inc.
Common Stock
S - Sale X -66,263 3,260,972 -1.99 9.43 -624,807 30,748,357
2020-06-23 2020-06-22 4 NK NantKwest, Inc.
Common Stock
M - Exercise 136,729 3,327,235 4.29 1.76 240,014 5,840,628
2020-06-23 2020-06-19 4 NK NantKwest, Inc.
Stock Option (right to buy)
M - Exercise -9,337 303,994 -2.98
2020-06-23 2020-06-19 4 NK NantKwest, Inc.
Common Stock
S - Sale X -13,737 3,190,506 -0.43 9.00 -123,637 28,715,511
2020-06-23 2020-06-19 4 NK NantKwest, Inc.
Common Stock
M - Exercise 9,337 3,204,243 0.29 1.76 16,390 5,624,728
2020-05-29 2020-05-27 4 NK NantKwest, Inc.
Common Stock
S - Sale X -75,000 3,194,906 -2.29 7.56 -567,338 24,167,866
2020-05-22 2020-05-21 4 NK NantKwest, Inc.
Common Stock
S - Sale X -36,932 3,269,906 -1.12 5.52 -203,698 18,035,167
2020-05-13 2020-05-11 4 NK NantKwest, Inc.
Common Stock
S - Sale X -28,068 3,306,838 -0.84 5.50 -154,509 18,203,482
2020-01-06 2020-01-02 4 CUE Cue Biopharma, Inc.
Stock Option (right to buy)
A - Award 9,600 9,600
2019-01-03 2019-01-02 4 CUE Cue Biopharma, Inc.
Stock Option (right to buy)
A - Award 9,600 9,600
2018-08-29 2018-08-27 4 NK NantKwest, Inc.
Stock Option (right to buy)
A - Award 200,000 200,000
2018-06-14 2018-06-12 4 CUE Cue Biopharma, Inc.
Stock Option (Right to Buy)
M - Exercise 8,000 8,000
2016-09-09 2016-09-08 4 NK NantKwest, Inc.
Common Stock
S - Sale -30,000 3,334,906 -0.89 7.40 -222,000 24,678,304
2016-09-09 2016-09-07 4 NK NantKwest, Inc.
Common Stock
S - Sale -2,000 21,143 -8.64 8.84 -17,671 186,811
2016-07-28 2016-07-27 4 NK NantKwest, Inc.
Restricted Stock Units
M - Exercise -185,150 0 -100.00
2016-07-28 2016-07-27 4 NK NantKwest, Inc.
Common Stock
F - Taxes -79,322 3,364,906 -2.30 6.89 -546,529 23,184,202
2016-07-28 2016-07-27 4 NK NantKwest, Inc.
Common Stock
M - Exercise 185,150 3,444,228 5.68
2015-08-05 2015-07-27 4 NK NantKwest, Inc.
Stock Option (right to buy)
A - Award 555,450 555,450
2015-08-05 2015-07-27 4 NK NantKwest, Inc.
Restricted Stock Units
M - Exercise -185,150 185,150 -50.00
2015-08-05 2015-07-27 4 NK NantKwest, Inc.
Restricted Stock Units
A - Award 370,300 370,300
2015-08-05 2015-07-27 4 NK NantKwest, Inc.
Common Stock
F - Taxes -96,612 3,259,078 -2.88 25.00 -2,415,300 81,476,950
2015-08-05 2015-07-27 4 NK NantKwest, Inc.
Common Stock
M - Exercise 185,150 3,355,690 5.84
2015-07-27 3 NK NantKwest, Inc.
Common Stock
6,341,080
2015-07-27 3 NK NantKwest, Inc.
Common Stock
6,341,080
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)